百濟神州(688235.SH)第三季度產品收入為23.93億元、同比上升92.2%
格隆匯11月9日丨百濟神州(688235.SH)公佈,2022年第三季度公司產品收入為23.93億元,較上年同比上升92.2%;2022年第三季度公司營業總收入為26.59億元,較上年同比上升99.1%。2022年前三季度公司產品收入為60.69億元,較上年同比上升114.6%;2022年前三季度公司營業總收入為68.69億元,較上年同比上升10.3%;2022年前三季度歸屬於母公司所有者的淨虧損104.34億元。報吿期末,公司總資產478.31億元,較年初減少13.3%;歸屬於母公司的所有者權益331.43億元,較年初減少17.0%。
2022年第三季度產品收入為23.93億元,上年同期產品收入為12.45億元,產品收入的增長主要得益於自主研發產品百悦澤®(澤布替尼膠囊)和百澤安®(替雷利珠單抗注射液)以及安進公司授權產品的銷售增長。2022年第三季度合作收入為2.66億元,主要來自於對與Novartis Pharma AG(“諾華製藥”)分別於2021年第一季度就PD-1抗體藥物百澤安®獲得的6.5億美元合作預付款、2021年第四季度就TIGIT抑制劑歐司珀利單抗(ociperlimab)的3億美元合作預付款進行的部分收入確認。上年同期合作收入為0.90億元,主要來自於對諾華製藥就百澤安®獲得的合作預付款進行的部分收入確認。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.